Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Germany will be the first launch market
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Subscribe To Our Newsletter & Stay Updated